EUVIMEDOpdag EUVIMED
Crossref

A long‐acting FGF21 attenuates metabolic dysfunction‐associated steatohepatitis‐related fibrosis by modulating NR4A1‐mediated Ly6C phenotypic switch in macrophages

Yue Ji, Yiliang Duan, Yuanyuan Li, Qingzhou Lu, Dingkang Liu, Yifan Yang, Ruilong Chang, Jing Tian, Wenbing Yao, Jun Yin, Xiangdong Gao iD

British Journal of Pharmacology · 2024-08 · 181 (16) · 2923-2946

DOI: 10.1111/bph.16378 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2024-04-28. Written by Yue Ji and 10 co-authors. Institution: Jiangsu Key Laboratory of Draggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, Ch…. Major MEDLINE topics: Fibroblast Growth Factors, Nuclear Receptor Subfamily 4, Group A, Member 1, Macrophages, Mice, Inbred C57BL. Cited 13 times so far (Crossref); 61 references. Funded by: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Key R&D Program of Xinjiang Uygur Autonomous Region.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Because of the absence of effective therapies for metabolic dysfunction‐associated steatohepatitis (MASH), there is a rising interest in fibroblast growth factor 21 (FGF21) analogues due to their potential anti‐fibrotic activities in MASH treatment. PsTag‐FGF21, a long‐acting FGF21 analogue, has demonstrated promising therapeutic effects in several MASH mouse models. However, its efficacy and mechanism against MASH‐related fibrosis remain less well defined, compared with the specific mechanisms through which FGF21 improves glucose and lipid metabolism. Experimental Approach The effectiveness of PsTag‐FGF21 was evaluated in two MASH‐fibrosis models. Co‐culture systems involving macrophages and hepatic stellate cells (HSCs) were employed for further assessment. Hepatic macrophages were selectively depleted by administering liposome‐encapsulated clodronate via tail vein injections. RNA sequencing and cytokine profiling were conducted to identify key factors involved in macrophage–HSC crosstalk. Key Results We first demonstrated the significant attenuation of hepatic fibrosis by PsTag‐FGF21 in two MASH‐fibrosis models. Furthermore, we highlighted the crucial role of macrophage phenotypic switch in PsTag‐FGF21‐induced HSC deactivation. FGF21 was demonstrated to regulate macrophages in a PsTag‐FGF21‐like manner. NR4A1, a nuclear factor which is notably down‐regulated in human livers with MASH, was identified as a mediator responsible for PsTag‐FGF21‐induced phenotypic switch. Transcriptional control over insulin‐like growth factor 1, a crucial factor in macrophage–HSC crosstalk, was exerted by the intrinsically disordered region domain of NR4A1. Conclusion and Implications Our results have elucidated the previously unclear mechanisms through which PsTag‐FGF21 treats MASH‐related fibrosis and identified NR4A1 as a potential therapeutic target for fibrosis.

Subjects

MeSH terms (MEDLINE)

Fibroblast Growth FactorsNuclear Receptor Subfamily 4, Group A, Member 1MacrophagesMice, Inbred C57BLAnimalsMiceMaleLiver CirrhosisHumansPhenotypeFatty LiverCells, CulturedHepatic Stellate Cells

Author keywords

FGF21Ly6CMASHNR4A1intercellular crosstalkliver fibrosismacrophage

Substances

Fibroblast Growth FactorsNuclear Receptor Subfamily 4, Group A, Member 1fibroblast growth factor 21Nr4a1 protein, mouseNR4A1 protein, human

Authors and institutions

  • Jiangsu Key Laboratory of Draggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.

ORCID profiles: Xiangdong Gao

Funding

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Key R&D Program of Xinjiang Uygur Autonomous Region
  • Postgraduate Research & Practice Innovation Program of Jiangsu Province
  • Innovation Team of the 'Double-First Class' Disciplines

Cite

APA

Ji, Y., Duan, Y., Li, Y., Lu, Q., Liu, D., Yang, Y., Chang, R., Tian, J., Yao, W., Yin, J., & Gao, X. (2024). A long‐acting FGF21 attenuates metabolic dysfunction‐associated steatohepatitis‐related fibrosis by modulating NR4A1‐mediated Ly6C phenotypic switch in macrophages. British Journal of Pharmacology, 181(16), 2923-2946. https://doi.org/10.1111/bph.16378

Vancouver

Ji Y, Duan Y, Li Y, Lu Q, Liu D, Yang Y, et al. A long‐acting FGF21 attenuates metabolic dysfunction‐associated steatohepatitis‐related fibrosis by modulating NR4A1‐mediated Ly6C phenotypic switch in macrophages. British Journal of Pharmacology. 2024;181(16):2923-2946. doi:10.1111/bph.16378

BibTeX
@article{Ji2024,
  author = {Ji, Yue and Duan, Yiliang and Li, Yuanyuan and Lu, Qingzhou and Liu, Dingkang and Yang, Yifan and Chang, Ruilong and Tian, Jing and Yao, Wenbing and Yin, Jun and Gao, Xiangdong},
  title = {A long‐acting FGF21 attenuates metabolic dysfunction‐associated steatohepatitis‐related fibrosis by modulating NR4A1‐mediated Ly6C phenotypic switch in macrophages},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {16},
  pages = {2923--2946},
  doi = {10.1111/bph.16378}
}
Start for free →